Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM. Sutton R, et al. Among authors: revesz t. Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30. Br J Haematol. 2018. PMID: 29194562 Free article.
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, Haber M, Norris MD, Fraser C, Alvaro F, Revesz T, Trahair TN, Dalla-Pozza L, Marshall GM, O'Brien TA. Sutton R, et al. Among authors: revesz t. Br J Haematol. 2015 Feb;168(3):395-404. doi: 10.1111/bjh.13142. Epub 2014 Oct 14. Br J Haematol. 2015. PMID: 25312094 Free article. Clinical Trial.
New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.
van der Velden VH, de Launaij D, de Vries JF, de Haas V, Sonneveld E, Voerman JS, de Bie M, Revesz T, Avigad S, Yeoh AE, Swagemakers SM, Eckert C, Pieters R, van Dongen JJ. van der Velden VH, et al. Among authors: revesz t. Br J Haematol. 2016 Mar;172(5):769-81. doi: 10.1111/bjh.13887. Epub 2015 Dec 21. Br J Haematol. 2016. PMID: 26898195 Free article.
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV. Irving JA, et al. Among authors: revesz t. Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26. Blood. 2016. PMID: 27229005 Free PMC article.
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Mateos MK, Marshall GM, Barbaro PM, Quinn MCJ, George C, Mayoh C, Sutton R, Revesz T, Giles JE, Barbaric D, Alvaro F, Mechinaud F, Catchpoole D, Lawson JA, Chenevix-Trench G, MacGregor S, Kotecha RS, Dalla-Pozza L, Trahair TN. Mateos MK, et al. Among authors: revesz t. Haematologica. 2022 Mar 1;107(3):635-643. doi: 10.3324/haematol.2020.268565. Haematologica. 2022. PMID: 33567813 Free PMC article.
CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
Fitter S, Bradey AL, Kok CH, Noll JE, Wilczek VJ, Venn NC, Law T, Paisitkriangkrai S, Story C, Saunders L, Dalla Pozza L, Marshall GM, White DL, Sutton R, Zannettino ACW, Revesz T. Fitter S, et al. Among authors: revesz t. Br J Haematol. 2021 Apr;193(1):171-175. doi: 10.1111/bjh.17161. Epub 2021 Feb 23. Br J Haematol. 2021. PMID: 33620089
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R. Marshall GM, et al. Among authors: revesz t. Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14. Leukemia. 2013. PMID: 23407458 Clinical Trial.
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.
Mateos MK, Trahair TN, Mayoh C, Barbaro PM, Sutton R, Revesz T, Barbaric D, Giles JE, Alvaro F, Mechinaud F, Catchpoole D, Kotecha RS, Dalla-Pozza L, Quinn MCJ, MacGregor S, Chenevix-Trench G, Marshall GM. Mateos MK, et al. Among authors: revesz t. Thromb Res. 2019 Jun;178:132-138. doi: 10.1016/j.thromres.2019.04.011. Epub 2019 Apr 11. Thromb Res. 2019. PMID: 31030032
Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia.
Schilstra CE, McCleary K, Fardell JE, Donoghoe MW, McCormack E, Kotecha RS, Lourenco RA, Ramachandran S, Cockcroft R, Conyers R, Cross S, Dalla-Pozza L, Downie P, Revesz T, Osborn M, Alvaro F, Wakefield CE, Marshall GM, Mateos MK, Trahair TN. Schilstra CE, et al. Among authors: revesz t. BMC Cancer. 2022 Sep 15;22(1):985. doi: 10.1186/s12885-022-10072-x. BMC Cancer. 2022. PMID: 36109702 Free PMC article.
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.
Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, Wilczek V, Budgen B, van Zanten K, Kuss BJ, Venn NC, Norris MD, Crock C, Storey C, Revesz T, Waters K. Morley AA, et al. Among authors: revesz t. J Mol Diagn. 2009 May;11(3):201-10. doi: 10.2353/jmoldx.2009.080048. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324989 Free PMC article.
559 results